Dalbavancin / Oritavancin / Telavancin

What it's for

Dalbavancin, oritavancin, and telavancin are semi-synthetic lipoglycopeptide antibiotics related to the vancomycin family, grouped here as a skin/infection library entry. They treat selected serious gram-positive infections, including acute bacterial skin and skin-structure infections (ABSSSI (serious bacterial skin infections)), per each drug’s label.

What it does for the body

They treat selected serious gram-positive infections, including acute bacterial skin and skin-structure infections (ABSSSI (serious bacterial skin infections)), per each drug’s label. People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.

What it targets

They bind the D-Ala-D-Ala terminus of peptidoglycan precursors, inhibiting cell-wall synthesis. Lipid tails improve anchoring and, for some agents, enable infrequent IV (into a vein) dosing. Researchers map these ideas in cells and animals first; human proof has to clear a higher bar.

Research context

Bottom line for readers: Dalbavancin / Oritavancin / Telavancin has a defined FDA-approved story. Use the citations tab to open labels and trial registries, and treat anything beyond the label as unverified.

Studied for (literature interest)

Skin research interest (educational tag)

Cautions (educational)

Educational only — not medical advice.
DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.

Citations / starters

FDA search: Dalbavancin / Oritavancin / Telavancin — FDA.gov search
ClinicalTrials.gov search: Dalbavancin / Oritavancin / Telavancin — U.S. clinical trials registry
Drugs@FDA search: Dalbavancin / Oritavancin / Telavancin — FDA drug database (if approved)
PubMed search: Dalbavancin / Oritavancin / Telavancin — NCBI PubMed
PubMed Central search: Dalbavancin / Oritavancin / Telavancin — NCBI PMC